ReviewCardiovascular drugs and therapy2026
Candidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence Appraisal.
Zhaoqi Yan et al.PubMed ↗Publisher ↗
No numbers read from the abstract.